Evidence map›Paper›PMID 31092419›Full record

ArticleAnticancer research2019

Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.

Huda I Atiya, Anna Dvorkin-Gheva, John Hassell, Shrusti Patel, Rachel L Parker, Adam Hartstone-Rose, Johnie Hodge, Daping Fan, Ann F Ramsdell

Open access · bronzeAbstract read
In one paragraph

Article in Anticancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Suppression of the malignancy of mammary tumor in mice model by inactivated preparation ofVeterinary research forum : an international quarterly journal · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Huda I AtiyaDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A.
Anna Dvorkin-GhevaDepartment of Biochemistry and Biomedical Science, McMaster University, Hamilton, ON, Canada.
John HassellDepartment of Biochemistry and Biomedical Science, McMaster University, Hamilton, ON, Canada.
Shrusti PatelDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A.
Rachel L ParkerDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A.
Adam Hartstone-RoseDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, U.S.A.
Johnie HodgeDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A.
Daping FanDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A.
Ann F RamsdellDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, U.S.A. ann.ramsdell@uscmed.sc.edu.
McMaster University · CANorth Carolina State University · US

Funding

South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0M
Emodin as a chemopreventive agent for breast cancer - admin suppR01CA218578 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI FAN, DAPING, MURPHY, ELIZABETH ANGELA · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA218578NIGMS NIH HHS P20 GM103499
6 · The paper itself

Abstract

backgroundLow success rates in oncology drug development are prompting re-evaluation of preclinical models, including orthotopic tumor engraftment. In breast cancer models, tumor cells are typically injected into mouse mammary fat pads (MFP). However, this approach bypasses the epithelial microenvironment, potentially altering tumor properties in ways that affect translational application. MATERIALS AND

methodsTumors were generated by mammary intraductal (MIND) engraftment of 4T1 carcinoma cells. Growth, histopathology, and molecular features were quantified.

resultsDespite growth similar to that of 4T1 MFP tumors, 4T1 MIND tumors exhibit distinct histopathology and increased metastasis. Furthermore, >6,000 transcripts were found to be uniquely up-regulated in 4T1 MIND tumor cells, including genes that drive several cancer hallmarks, in addition to two known therapeutic targets that were not up-regulated in 4T1 MFP tumor cells.

conclusionEngraftment into the epithelial microenvironment generates tumors that more closely recapitulate the complexity of malignancy, suggesting that intraductal adaptation of orthotopic mammary models may be an important step towards improving outcomes in preclinical drug screening and development.

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorDisease Models, AnimalFemaleHumansMammary Neoplasms, AnimalMiceMolecular Targeted TherapyNeoplasm MetastasisNeoplasm ProteinsNeovascularization, PathologicTumor MicroenvironmentNeoplasm ProteinsMammary carcinomamammary epitheliummicroenvironmentorthotopic tumor modeltriple-negative breast cancer

Identifiers

PMID31092419
PMCPMC7339129
OpenAlexW2946503794

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.